Daiichinkyo CoFRA:D4S -0.07%80 Market Cap is €25,764 Mil as of Jul. 01, 2026. GuruFocus rates FRA:D4S with a GF Score™ of 80/100 and a GF Value™ of €33.49 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,022 Drug Manufacturers companies, Daiichinkyo Co ranks better than 97.26% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Daiichinkyo Co's share price for the quarter that ended in Mar. 2026 was €15.005. Daiichinkyo Co's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 1,820 Mil. Therefore, Daiichinkyo Co's market cap for the quarter that ended in Mar. 2026 was €27,304 Mil.
Daiichinkyo Co's quarterly market cap
declined
from Sep. 2025 (€35,077 Mil) to Dec. 2025 (€34,263 Mil) and
declined
from Dec. 2025 (€34,263 Mil) to Mar. 2026 (€27,304 Mil).
Daiichinkyo Co's annual market cap
declined
from Mar. 2024 (€57,122 Mil) to Mar. 2025 (€40,245 Mil) and
declined
from Mar. 2025 (€40,245 Mil) to Mar. 2026 (€27,304 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Daiichinkyo Co's Enterprise Value for Today is €24,385 Mil.
Daiichinkyo Co (FRA:D4S) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Daiichinkyo Co Market Cap Related Terms
Daiichinkyo Co Market Cap Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Market Cap distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Daiichinkyo Co's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiichinkyo Co (FRA:D4S) has a Market Cap of €25,764 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Daiichinkyo Co and its competitors. According to the industry distribution chart, Daiichinkyo Co ranks #28 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 2.7%.
Is Daiichinkyo Co's Market Cap too high?
Daiichinkyo Co's current Market Cap is €25,764 Mil. Based on the distribution chart, Daiichinkyo Co ranks #28 out of 1022 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Daiichinkyo Co has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Market Cap compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #28 out of 1022 companies for Market Cap. This places Daiichinkyo Co in the top 3% of its industry — outperforming the majority of peers. The industry median Market Cap is 210.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Market Cap is €25,764 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (FRA:D4S) is currently considered Significantly Undervalued. The stock's GF Value™ is €33.49, compared to a current price of €14.36 — trading 57.1% below its estimated fair value. The current Market Cap is €25,764 Mil. Daiichinkyo Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Daiichinkyo Co (FRA:D4S), the current Market Cap is €25,764 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (FRA:D4S) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of €14.36 is trading 57.1% below its estimated GF Value™ of €33.49.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for FRA:D4S:
Market Cap: €25,764 Mil
GF Value™: €33.49 vs. price of €14.36 (57.1% below fair value)
No single metric tells the full story. See the FRA:D4S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
80GF Score
Get the complete analysis for FRA:D4S
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D4S has been successfully added to your 
